ID
45979
Descrizione
Principal Investigator: Ellen L. Goode, Mayo Clinic, Rochester, MN, USA MeSH: Cystadenocarcinoma, Serous,Ovarian Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000897 Twenty five patients with early stage carcinoma (Stage I and II) of the ovary were consented for this study. As part of a collaborative agreement with Illumina Inc, Tumor-DNA and patient matched normal DNA from blood underwent whole genome sequencing and microarray genotyping and RNA underwent RNASeq. Tissue also underwent IHC staining for TP53 mutations. The aim of the study was to profile the genomic landscape of these early tumors to discover biomarkers for early detection or subgrouping into different genomic or outcome subgroups. Analyses performed include somatic mutation analysis, RNASeq mutation analysis, LOH analysis, structural variant detection. The current release of this study focusses on 17 patients with serous carcinoma and stage 1 or 2 and with high grade (3 or 4).
collegamento
Keywords
versioni (1)
- 02/04/24 02/04/24 - Madita Rudolph
Titolare del copyright
Ellen L. Goode, Mayo Clinic, Rochester, MN, USA
Caricato su
2 aprile 2024
DOI
Per favore, per richiedere un accesso.
Licenza
Creative Commons BY 4.0
Commenti del modello :
Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.
Commenti del gruppo di articoli per :
Commenti dell'articolo per :
Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.
dbGaP phs000897 Mayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, subject source, source subject ID, and affection status of participants with ovarian cancer and involved in the "CMayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study" project.
- Subject ID, sample ID, and sample use variable obtained from participants with ovarian cancer and involved in the "CMayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study" project.
- Subject ID, age, clinical trial, tumor characteristics including ascites status, CA125 measurement, tumor stage and grade, malignancy, tumor morphology, remission, cytology, recurrence, residual tumor, pathological review, tumor site, cause of death, diagnostic, chemotherapy, and surgery of participants with ovarian cancer and involved in the "CMayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status, and histological type of sample obtained from participants with ovarian cancer and involved in the "CMayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study" project.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, subject source, source subject ID, and affection status of participants with ovarian cancer and involved in the "CMayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study" project.
- Subject ID, sample ID, and sample use variable obtained from participants with ovarian cancer and involved in the "CMayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study" project.
- Subject ID, age, clinical trial, tumor characteristics including ascites status, CA125 measurement, tumor stage and grade, malignancy, tumor morphology, remission, cytology, recurrence, residual tumor, pathological review, tumor site, cause of death, diagnostic, chemotherapy, and surgery of participants with ovarian cancer and involved in the "CMayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status, and histological type of sample obtained from participants with ovarian cancer and involved in the "CMayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study" project.
C0680251 (UMLS CUI [1,2])
C1706256 (UMLS CUI [1,2])
C0029925 (UMLS CUI [1,3])
C0680251 (UMLS CUI [2,1])
C0241889 (UMLS CUI [2,2])
C1511022 (UMLS CUI [2,3])
C1511024 (UMLS CUI [2,4])
C0206530 (UMLS CUI [2,5])
C0006826 (UMLS CUI [1,2])
C0440743 (UMLS CUI [1,3])
C0019638 (UMLS CUI [1,4])